A 12-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease
The purpose of this study is to collect information on the safety of AT1001 (migalastat hydrochloride) and how AT1001 works in patients with Fabry disease.
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase 2, Open-Label, Single Dose Level, 12-Week Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AT1001 in Patients With Fabry Disease|
- Primary: Safety and tolerability. [ Time Frame: All visits ] [ Designated as safety issue: Yes ]
- Secondary: Pharmacodynamic and functional (cardiac, CNS/PNS, and renal) parameters. [ Time Frame: All visits ] [ Designated as safety issue: Yes ]
|Study Start Date:||March 2006|
|Study Completion Date:||May 2008|
|Primary Completion Date:||May 2008 (Final data collection date for primary outcome measure)|
Experimental: 150 mg capsule
oral migalastat HCl (AT1001) administered every other day.
Drug: AT1001 (migalastat hydrochloride)
administered every other day
The purpose of this study is to determine the effect of AT1001 given orally to patients with Fabry disease. Patients will visit the clinic 4 weeks prior to dosing to determine their eligibility for the study, and then return for a second visit for baseline and safety assessments, which will include skin, cardiac, and renal biopsies. Patients will receive oral doses of AT1001 for 12 weeks and will visit the clinic 3 more times, once every 4 weeks, for evaluation and tests. Skin, cardiac, and renal biopsies, and functional assessments will be performed at the end of the 12 week period. Patients may be given the opportunity to enter a study extension phase for an additional 36 weeks, which will require three more clinic visits, and a final set of functional tests and biopsies. All study participants will have a final follow up visit 2 weeks after the end of the study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00283959
|Royal Melbourne Hospital, Department of Nephrology|
|Parkville, Victoria, Australia, 3050|
|Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre|
|Porto Alegre, Brazil|
|Principal Investigator:||Roberto Giugliani, MD, PhD||Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre|